In:
International Journal of Cancer, Wiley, Vol. 145, No. 4 ( 2019-08-15), p. 979-993
Kurzfassung:
What's new? Anlotinib, a novel multitargeted tyrosine kinase inhibitor newly approved by China Food and Drug Administration, has demonstrated potent clinical benefit in several types of solid tumors including non‐small cell lung cancer and soft tissue sarcoma. Its effect on osteosarcoma remains understudied, however. Using different preclinical models, here the authors demonstrate the anti‐tumor activity of anlotinib in osteosarcoma, showing that anlotinib inhibits osteosarcoma growth, metastasis and angiogenesis via dual blockade of VEGFR2 and MET signaling pathways in vitro and in vivo . The preclinical findings highlight anlotinib as a promising agent for treating advanced osteosarcoma patients.
Materialart:
Online-Ressource
ISSN:
0020-7136
,
1097-0215
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2019
ZDB Id:
218257-9
ZDB Id:
1474822-8
